Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

(S)-crizotinib

Home Drugs(S)-crizotinib

(S)-crizotinib

Unknown Manufacturer

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Crizotinib derivative as well as preparation method and application thereof
Applicant: UNIV ZHEJIANG SHURENPriority: 2018
CN
Novel synthesis method of crizotinib intermediate
Applicant: NANJING ANHUAI INNOVATIVE DRUG RES INSTITUTE CO LTDPriority: 2020
CN
TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION USING (S)-CRIZOTINIB
Applicant: VANDA PHARMACEUTICALS INCPriority: 2022
US
Application of crizotinib as well as analogue and medicinal salt thereof in preparation of medicine for treating ferroptosis related diseases
Applicant: UNIV CHONGQING MEDICALPriority: 2024
CN
Synthesis method of crizotinib intermediate
Applicant: CHONGQING SHENGHUAXI PHARMACEUTICAL CO LTDPriority: 2024
CN
Preparation method of crizotinib
Applicant: GUANGZHOU KERUITE PHARMACEUTICAL CO LTDPriority: 2026
CN